AN2 Therapeutics, Inc. (ANTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ANTX currently has 34.1M outstanding shares. with significant dilution risk as 71.6M authorized shares could dilute existing holders by 210.2%. The company has significantly diluted shareholders by 56.5% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 11, 2026 |
10-Q filing | 34.1M shares outstanding |
34M | 72M |
| Apr 09, 2026 |
S-3 filing: This S-3 filing from AN2 Therapeutics, Inc. details a shelf registration for up to $300,000,000 in the aggregate of common stock, preferred stock, and debt securities offered by the company, as well as 14,035,104 shares of common stock offered by selling securityholders. |
27M | 72M |
| Mar 17, 2026 |
10-K filing | 35.9M shares outstanding |
36M | 34M |
| Nov 12, 2025 |
10-Q filing | 27.4M shares outstanding |
27M | 34M |
| Aug 12, 2025 |
10-Q filing | 27.3M shares outstanding |
27M | 34M |
| May 13, 2025 |
10-Q filing | 30.1M shares outstanding |
30M | 34M |
| Mar 25, 2025 |
10-K filing | 29.8M shares outstanding |
30M | 34M |
| Nov 13, 2024 |
10-Q filing | 29.8M shares outstanding |
30M | 34M |
| Aug 13, 2024 |
10-Q filing | 29.8M shares outstanding |
30M | 34M |
| May 14, 2024 |
10-Q filing | 29.8M shares outstanding |
30M | 34M |
| Mar 29, 2024 |
10-K filing | 29.8M shares outstanding |
30M | 34M |
| Nov 09, 2023 |
10-Q filing | 29.7M shares outstanding |
30M | 34M |
| Aug 10, 2023 |
10-Q filing | 21.9M shares outstanding |
22M | 34M |
| May 11, 2023 |
10-Q filing | 19.4M shares outstanding |
19M | 34M |
| Apr 06, 2023 |
S-3 filing: AN2 Therapeutics, Inc. is filing an S-3 to offer and sell up to $300,000,000 of any combination of common stock, preferred stock and debt securities. |
19M | 34M |
| Mar 29, 2023 |
10-K filing | 19.4M shares outstanding |
19M | 0 |
| Nov 09, 2022 |
10-Q filing | 19.3M shares outstanding |
19M | 0 |
| Aug 11, 2022 |
10-Q filing | 19.3M shares outstanding |
19M | 0 |
| May 10, 2022 |
10-Q filing | 19.4M shares outstanding |
19M | 0 |
| Mar 21, 2022 |
S-1/A filing: S-1/A filing for an offering underwritten by Cowen, SVB Leerink, Evercore ISI, and Oppenheimer & Co. Lock-up agreements are in place for 180 days after the pricing of the offering. |
N/A | 0 |
| Mar 04, 2022 |
S-1 filing: S-1 filing for an offering underwritten by Cowen, SVB Leerink, Evercore ISI, and Oppenheimer & Co. Lock-up agreements are in place for 180 days after the pricing date. |
N/A | 0 |